康诺生物制药

Chengdu Kangnuo Biopharmaceutical is a specialized Chinese pharmaceutical company focused on the research, development, and industrialization of peptide-based therapeutics. Established in 2005 and headquartered in Chengdu, the company has developed a leading technology platform for large-scale solid-phase peptide synthesis, enabling the production of high-purity APIs and finished dosage forms. Their commercial portfolio includes essential peptide treatments such as Teriparatide for osteoporosis, Thymalfasin for immune modulation, and Bivalirudin for anticoagulation. Kangnuo Biopharmaceutical operates GMP-certified manufacturing facilities and provides comprehensive CDMO services to global pharmaceutical partners. The company is a key player in the Chinese peptide market, continuously expanding its pipeline into metabolic, endocrine, and cardiovascular therapeutic areas.